Table 1.
Characteristics of the patients and intraoperative data
| TMZ (n = 40) | Placebo (n = 40) | P | |
|---|---|---|---|
| Age, years | 65 ± 6 | 64 ± 8 | 0.86 |
| Men, n (%) | 28 (70.0) | 26 (65.0) | 0.92 |
| BMI (Kg/m2) | 26.3 ± 3.2 | 26.2 ± 3.3 | 0.74 |
| NYHA classification, n (%) | |||
| I | 12 (30.0) | 13 (32.5) | 0.85 |
| II | 18 (45.0) | 19 (47.5) | 0.95 |
| III | 7 (17.5) | 6 (15.0) | 0.64 |
| IV | 3 (7.5) | 2 (5.0) | 0.35 |
| ASA classification, n (%) | |||
| II | 6 (15.0) | 7 (17.5) | 0.64 |
| III | 30 (75.0) | 28 (70.0) | 0.76 |
| IV | 4 (10.0) | 5 (12.5) | 0.85 |
| History of smoking, n (%) | 12 (30) | 10 (25) | 0.72 |
| History of dyslipidemia, n (%) | 25 (62.5) | 21 (52.5) | 0.58 |
| History of hypertension, n (%) | 11 (27.5) | 13 (32.5) | 0.80 |
| History of CAD, n (%) | 31 (77.5) | 32 (80.0) | 0.86 |
| History of percutaneous intervention or CABG for CAD, n (%) | 8 (20) | 9 (22.5) | 0.79 |
| History of stroke, n (%) | 5 (12.5) | 4 (10.0) | 0.85 |
| History of diabetes mellitus, n (%) | 10 (25.0) | 9 (22.5) | 0.75 |
| Medication history, n (%) | |||
| ß-blockers | 29 (72.5) | 31 (77.5) | 0.76 |
| ACEI/ARB | 30 (75.0) | 32 (80.0) | 0.82 |
| Statins | 26 (65.0) | 27 (67.5) | 0.89 |
| Insulin | 4 (10.0) | 3 (7.5) | 0.85 |
| Oral anti-diabetic drugs only | 10 (25.0) | 11 (27.5) | 0.88 |
| Antiplatelet agents | 16 (40) | 14 (35) | 0.74 |
| Type of surgery, n (%) | |||
| Major general | 11 (27.5) | 15 (37.5) | 0.56 |
| Major orthopedic | 21 (52.5) | 19 (47.5) | 0.64 |
| Major vascular | 8 (20.0) | 6 (15.0) | 0.80 |
| Preoperative troponin elevation, n (%) | 2 (5.0) | 3 (7.5) | 0.45 |
| Operation duration (min) | 156 ± 24 | 162 ± 28 | 0.79 |
| Blood loss (ml) | 256 ± 146 | 267 ± 165 | 0.62 |
| BIS values | 45 ± 12 | 46 ± 14 | 0.83 |
TMZ, trimetazidine; BMI, body mass index; NYHA, New York Heart Association; ASA, American Society of Anesthesiologists; CAD, coronary artery disease; CABG, coronary artery bypass grafting; ACE, angiotensin-converting enzyme; BIS, bispectral index